Search
Humacyte Inc
HUMAAdd to Watchlist
0.592USD
+0.002+0.34%
Close 11-11 16:00（ET）
164.46MMarket Cap
LossP/E TTM
Pre-market 05:55 (ET)0.590USD-0.002-0.34%
Pre-market 05:55 (ET)Humacyte Inc (HUMA) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Humacyte Inc in the past month.
Buy
1 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
1.625USD+295.18%
HUMA Analyst Recommendation Trends
In the current month, HUMA has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HUMA average Analyst price target in the last month is 1.625.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
1
1
1
1
1
1
3
3
3
3
3
5
5
5
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
7
7
7
HUMA Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, HUMA EPS is projected to reach -0.089 in FY2026Q3, following reported EPS of -0.157 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.13
-0.12
-0.10
-0.09
-0.08
Actual
-0.13
-0.09
-0.16
--
--
Surprise
-0.68%
+23.33%
-57.15%
--
--
FAQs
What is Humacyte Inc's expected revenue for the next quarter?
Humacyte Inc's expected revenue is 766.00K.
What is Humacyte Inc's price target?
Analysts forecast that Humacyte Inc's price target is USD 1.62, with the highest forecast at USD 4.00 and the lowest forecast at USD 0.50.
How have Humacyte IncHUMA's recent earnings per share performed?
The market expectation was USD -0.16, while Humacyte IncHUMA's earnings per share (EPS) for the previous quarter was USD -0.09. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Humacyte Inc?
Based on the ratings of Humacyte Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.